hPG80 (Circulating Progastrin), a novel blood-based biomarker for detection of well-differentiated neuroendocrine tumors

#3274

Introduction: Current blood-based biomarkers for neuroendocrine tumors (NETs) lack both sensitivity and specificity. Human circulating progastrin (hPG80) is a novel biomarker for NETs and is easily measured in plasma using an ELISA test.

Aim(s): This study is the first to explore hPG80 in NETs.

Materials and methods: Progastrin concentrations were quantified in plasma from 70 patients with stage IV NETs using DxPG80 technology (ECS Progastrin, Switzerland) and compared with hPG80 concentrations in 50-80-year-old healthy donors (n=252) as well as a subgroup comprised of only the 18-25-year-olds (n=137).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chauhan A, Prieur A, Kolesar J, Arnold S, Cousin T,

Keywords: neuroendocrine tumor, progastrin, hPG80, blood-based biomarker,